CDP 923
Alternative Names: NB-DGJ; OGT 923Latest Information Update: 21 Sep 2007
At a glance
- Originator Oxford Glycobiology Institute
- Class Glycolipids
- Mechanism of Action Glucosylceramide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
- 05 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group
- 08 Nov 2002 Phase-I clinical trials in Metabolic disorders in United Kingdom (unspecified route)